Custom Antibody Market Overview:
The custom antibody market is projected to grow at a CAGR of approximately 10% throughout the forecast period. This expansion is driven by increasing R&D activity, rising demand for highly specific antibodies, greater adoption of targeted therapeutics, and continuous advancements in antibody engineering and production technologies. However, high development costs and the time-consuming nature of antibody generation continue to pose challenges that may slow broader market adoption.
Year-End Mega Sale: Get Up to 10% Off on All Market Research Reports!
Custom antibodies play a critical role in life science research, clinical diagnostics, and therapeutic development. These laboratory-engineered antibodies are designed to recognize and bind to specific antigens that often cannot be targeted effectively using commercially available alternatives. Their production typically involves steps such as antigen synthesis, animal immunization (commonly using rabbits, mice, or goats), serum collection, and purification.
Competitive Landscape Analysis
The global custom antibody market is marked by the presence of established and emerging market players such as Thermo Fisher Scientific Inc.; Abcam plc; Bio-Rad Laboratories, Inc; Creative Biolabs; Merck KGaA; Agilent Technologies Inc; GenScript; Laboratory Corporation of America; Danaher Corporation; Kaneka Eurogentec S.A.; Bio-Techne; and Sino Biological, Inc., among others. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.
Targeted therapeutics continue to drive market momentum
A major factor fueling market growth is the rising emphasis on precision medicine and targeted therapeutics. As research into complex diseases—such as cancer, autoimmune disorders, and infectious diseases—advances, scientists increasingly require highly selective antibodies to detect, study, and manipulate disease-associated proteins. Recent collaborations underscore this trend. For example, in June 2025, BioNTech and Bristol Myers Squibb formed a global partnership to co-develop and commercialize BNT327, BioNTech’s next-generation bispecific PD-L1 × VEGF-A antibody intended for multiple solid tumor types.
Custom antibodies’ capacity to bind precisely to unique epitopes enhances diagnostic accuracy and strengthens therapeutic efficacy. Pharmaceutical and biotechnology companies are investing heavily in custom antibody development to support the creation of antibody-drug conjugates (ADCs) and other complex biologics. A notable example occurred in December 2022, when Merck entered an exclusive licensing and collaboration agreement with Kelun-Biotech to co-develop seven preclinical ADC candidates for oncology applications. These advancements continue to broaden the scope and demand for custom antibodies.
Download Sample Copy: https://meditechinsights.com/custom-antibody-market/request-sample/
Technological innovation and collaboration enhance custom antibody capabilities
Rapid progress in biotechnology has further solidified the role of custom antibodies as essential research and clinical tools. Phage display technology represents one significant advancement, enabling scientists to screen billions of antibody variants quickly and identify those with optimal target specificity. Its speed, scalability, and precision have driven widespread adoption across both industry and academic settings.
Collaborative efforts are also accelerating innovation. In December 2024, Antibody Solutions became an approved CRO for Levena’s Singularity™ SAPIEN™ Mouse platform, a transgenic model designed to generate high-affinity, human-derived antibodies more efficiently for diagnostic and therapeutic use. Similarly, in March 2024, Sino Biological entered a partnership with Rapid Novor to integrate Rapid Novor’s REmAb monoclonal antibody sequencing technology with Sino Biological’s custom antibody development services—creating a seamless workflow from antibody discovery to final production.
As technological capabilities expand and collaborative networks strengthen, the development of high-quality custom antibodies is becoming more efficient, reproducible, and accessible. These advancements are lowering entry barriers and enabling broader adoption across research institutions, diagnostic developers, and biotechnology companies.
Global Custom Antibody Market Segmentation
This report by Medi-Tech Insights provides the size of the global custom antibody market at the regional- and country-level from 2023 to 2030. The report further segments the market based on type, service, source, application, and end-user.
Market Size & Forecast (2023-2030), By Type, USD Million
- Monoclonal Antibodies
- Polyclonal Antibodies
- Recombinant Antibodies
- Others
Market Size & Forecast (2023-2030), By Service, USD Million
- Antibody Development
- Antibody Production & Purification
- Antibody Fragmentation & Labelling
Market Size & Forecast (2023-2030), By Source, USD Million
- Mice
- Rabbit
- Others
Market Size & Forecast (2023-2030), By Application, USD Million
- Oncology
- Infectious Diseases
- Neurology
- Stem cells
- Immunology
- Cardiovascular Diseases
- Others
Market Size & Forecast (2023-2030), By End-user, USD Million
- Hospitals & Clinics
- Academic & Research Institutes
- CRO
- Others
Market Size & Forecast (2023-2030), By Region, USD Million
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- India
- Japa
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
About Medi-Tech Insights;
Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
